Comparison · NCT00105534-5e36e796
AzaSite vs Vehicle: Participants Who Achieved Bacteriological Eradication
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AzaSite vs Vehicle: Participants Who Achieved Bacteriological Eradication. Trial comparisons, record NCT00105534-5e36e796. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00105534-5e36e796
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.885 | 0.818 | 0.929 | wilson | |
| Risk in group 2 | 0.664 | 0.585 | 0.735 | wilson | |
| Risk difference, group 1 minus group 2 | 0.22 | 0.123 | 0.311 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 1.17 | 1.52 | log | |
| Odds ratio, group 1 over group 2 | 3.87 | 2.05 | 7.32 | log | |
| Number needed to treat, for one more participant with the outcome on AzaSite than on Vehicle | 4.54 | 3.22 | 8.12 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AzaSite | 115 | 130 | OG000 | |
| Group 2 | Vehicle | 99 | 149 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants Who Achieved Bacteriological Eradication
- Description
- Bacterial eradication is defined as the eradication of the causative pathogens as indicated by the absence of growth (0 colony forming units/mL) of the original infecting organism(s).
- Time frame
- Visit 3 (Day 6-7)
- Population
Per protocol population (defined as all randomized participants who had administered at least one drop of study drug, who had eye cultures indicating pathogenic bacteria levels as well as the clinical signs of conjunctivitis at Visit 1 and had at least one post first dose clinical assessment) with last observation carried forward.
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
- NCT number
- NCT00105534
- Phases
- PHASE3
- Conditions
- Bacterial Conjunctivitis
- Interventions
- AzaSite, Vehicle
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2011-10-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00105534?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00105534-5e36e796